Christine Hann, M.D., Ph.D.

Phone: 410-955-8964

Titles

Assistant Professor of Oncology

Schools/Degrees

M.D., Jefferson Medical College
Ph.D., Thomas Jefferson University

Training

Resident, Internal Medicine, University of Chicago Hospitals
Hematology and Medical Oncology Fellowship, Johns Hopkins University

Certifications

Internal Medicine and Medical Oncology

Clinical Interests

Lung cancer

Research Summary

Dr. Hann is a member of the Upper Aerodigestive Cancer Program with a primary focus on developing novel therapeutics for lung cancer, particularly small cell lung cancer.  As a post-doctoral fellowship her research focused on the preclinical evaluation of a novel small molecule inhibitor which is currently in Phase I/II clinical trials.  She is the recipient of several awards including an ASCO Young Investigator Award and a FAMRI Young Clinical Scientist Award.  As a faculty member, she sees patients with non-small cell and small cell lung cancer and conducts innovative research with both basic biological and major clinical implications.

VW 3/08

Journal Citations

Gallia, G. L., Sciubba, D. M., Hann, C. L., Raman, S. P., Westra, W. H., Tufaro, A. P. & Olivi, A. (2005). Synovial sarcoma of the frontal sinus. Case report. J Neurosurg 103, 1077-80.

Gallia, G.L., Tyler, B.M., Hann, C.L., Sui, I.M., Giranda, C., Vescovi, A., Brem, H., and Riggins, G.J. (2009). Inhibition of Akt inhibitor growth of glioblastoma stem-like cells. Mol Cancer Therapeutics.  8, 386-393.

Hann, C. L., and C. M. Rudin. 2007. Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer. Trends Mol Med 13:150-7.

Hann, C. L., and J. R. Brahmer. 2007. "Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?" Curr Treat Options Oncol 8:28-37.

Hann, C. L., and M. B. Streiff. 2007. "Vena caval filters", p. 531-552. In C. S. Kitchens, B. M. Alving, and C. M. Kessler (ed.), Consultative Hemostasis and Thrombosis, 2nd ed. Elsevier Press, Philadelphia.

Hann, C. L., V. C. Daniel, J. Hierman, E. Sugar, L. Cope, M. Lin, D. N. Watkins, and C. M. Rudin. 2008.. Therapeutic Efficacy of ABT-737, a selective inhibitor of bcl-2, in small cell lung cancer. Cancer Res. 68:2321-2328.

Hann, C.L., and Rudin, C.M. (2008). Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park, N.Y 22, 1486-1492; discussion 1493-1486, 1498-1500, 1506.

Hann, C.L., Daniel, V.C., Sugar, E.A., Dobromilskaya, I., Murphy, S.C., Cope, L., Lin, X., Hierman, J.S., Wilburn, D.L., Watkins, D.N., and Rudin, C.M. (2008). Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 68, 2321-2328.

Rudin, C.M., Hann, C.L., Peacock, C.D., and Watkins, D.N. (2008). Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw 6, 315-322.

Hann CL and JR Brahmer. Who should receive epidermal growth factor receptor inhibitors for NSCLC and when? Curr Treat Options Oncol 2007 Feb;8(1):28-37.

Hann CL and JR Brahmer. Second-line therapy for advanced non-small-cell lung cancer. Curr Oncol Rep. 2006; 8(4):243-247.